Provided By GlobeNewswire
Last update: Feb 28, 2024
- Updated dose escalation data from SNS-101 clinical study supports favorable and potentially best-in-class safety and PK profile both as monotherapy and in combination with PD-1 blockade -
NASDAQ:SNSE (7/11/2025, 8:00:02 PM)
8.1654
-0.93 (-10.27%)
Find more stocks in the Stock Screener